26 Nov 2019 --- The supplementation of Farlong Pharmaceutical’s NotoGinseng is well tolerated by most people, as well as having a positive influence on reducing the risk of cardiovascular disease by decreasing blood pressure and selectively increasing high-density lipoprotein cholesterol (HDL-C). This is according to the clinical trial results from a nearly three-year-long study on 100 healthy adults to determine the effect of the NotoGinseng on cholesterol and blood pressure. The study’s findings present a means to help US adults prevent cardiovascular disease.
